Posterior uveitis
diseaseOn this page
Also known as chorioretinal region inflammationinflammation of chorioretinal region
Summary
Posterior uveitis (MONDO:0006918) is a disease and 14 clinical trials. Top therapeutic interventions include cyclosporine and sotrastaurin. A subtype of uveitis — broader associated-gene and molecular evidence is on the parent page (see Disease family below).
At a glance
- Clinical trials: 14
Clinical features
No curated clinical features (Orphanet) for this disease.
Identifiers
Disease identifiers
| Field | Value |
|---|---|
| Canonical name | posterior uveitis |
| Mondo ID | MONDO:0006918 |
| EFO | EFO:1001119 |
| MeSH | D015866 |
| DOID | DOID:12574 |
| SNOMED CT | 43363007 |
| UMLS | C0042167 |
| MedGen | 22597 |
| GARD | 0024501 |
| MedDRA | 10036370 |
| Is cancer (heuristic) | no |
Also known as: chorioretinal region inflammation · inflammation of chorioretinal region
Disease family
This is a subtype of uveitis. Genetic, therapeutic, and trial evidence is largely curated at the broader-term level — see the parent page for the associated-gene cohort and molecular evidence.
Classification path: disease › human disease › disease by body system or component › disorder of orbital region › eye disorder › uveal disorder › uveitis › posterior uveitis
Related subtypes (8): chorioretinitis, anterior uveitis, intermediate uveitis, iritis, suppurative uveitis, panuveitis, idiopathic posterior uveitis, autoimmune uveitis
Subtypes (3): choroiditis, retinitis, birdshot chorioretinopathy
Genetics & variants
GWAS landscape
No GWAS associations recorded — common-variant (GWAS) studies don’t cover this disease (typical for Mendelian / rare diseases). See the curated gene cohort and Mendelian overlap below.
Variant details and genetic-evidence tiers
No tiered GWAS variants or ClinVar records for this disease.
Genes & proteins
No associated-gene cohort resolved for this disease. Atlas builds the molecular and therapeutic sections — associated genes, protein families, druggability, pathways, interactions, and drug associations — by aggregating over a disease’s associated genes (resolved via GWAS / GenCC / ClinVar / CIViC), and none resolved here. This is expected for antibody-mediated, autoimmune, or otherwise non-gene-defined conditions; the curated evidence for this disease is its clinical features, GWAS susceptibility, and clinical trials (above).
Function
No pathway enrichment — requires an associated-gene cohort.
Therapeutics
Drugs indicated for this disease
5 approved, 2 in late-stage (phase 3) trials. Disease-direct ChEMBL indications, not inferred from the associated-gene cohort below.
| Drug | Development status |
|---|---|
| Cortisone Acetate | Approved (phase 4) |
| Dexamethasone | Approved (phase 4) |
| Methylprednisolone | Approved (phase 4) |
| Prednisolone | Approved (phase 4) |
| Prednisone | Approved (phase 4) |
| Fluocinolone Acetonide | Phase 3 (in late-stage trials) |
| Voclosporin | Phase 3 (in late-stage trials) |
Earlier-phase candidates (phase 2, investigational — efficacy not yet established): Piclidenoson, Sirolimus.
Clinical trials & evidence
Clinical trials
Clinical trials: 14.
Phase distribution (across all retrieved trials)
| Phase | Trials |
|---|---|
| Not specified | 5 |
| PHASE3 | 2 |
| PHASE2 | 2 |
| PHASE1/PHASE2 | 2 |
| PHASE4 | 1 |
| PHASE2/PHASE3 | 1 |
| PHASE1 | 1 |
Top trials by phase / activity
| NCT | Phase | Status | Title |
|---|---|---|---|
| NCT02764697 | PHASE4 | COMPLETED | Study of H.P. ACTHAR Subcutaneous Gelatin (Gel)(Highly Purified Gel Injection) in Uveitis Patients |
| NCT00167583 | PHASE3 | COMPLETED | Interferon-alpha2a Versus Cyclosporin A for Severe Ocular Behcet’s Disease (INCYTOB) |
| NCT00333814 | PHASE2/PHASE3 | COMPLETED | A Study of the Safety and Efficacy of a New Treatment for Non-Infectious Intermediate or Posterior Uveitis |
| NCT02746991 | PHASE3 | COMPLETED | Safety and Efficacy Study of a FAI Insert in Subjects With Chronic Non-infectious Posterior Uveitis |
| NCT00615693 | PHASE2 | COMPLETED | Safety, Tolerability, and Efficacy of AEB071 in the Treatment of Uveitis |
| NCT01280669 | PHASE2 | WITHDRAWN | Intravitreal Sirolimus as Therapeutic Approach to Uveitis |
| NCT01717170 | PHASE1/PHASE2 | UNKNOWN | Study of the Safety, Tolerability, and Bioactivity of Tocilizumab On Patients With Non-infectious UVEITIS: The STOP-UVEITIS Study |
| NCT01789320 | PHASE1/PHASE2 | COMPLETED | Safety Study of Suprachoroidal Triamcinolone Acetonide Via Microneedle to Treat Uveitis |
| NCT00908466 | PHASE1 | COMPLETED | Sirolimus as Therapeutic Approach to Uveitis |
| NCT05153057 | Not specified | RECRUITING | Birdshot Chorioretinopathy : Prospective Follow-up and Immunogenetic Studies(CO-BIRD) |
| NCT00407316 | Not specified | UNKNOWN | Quality of Life and Visual Function in Uveitis Patients |
| NCT00570830 | Not specified | COMPLETED | Retisert and Cataract Surgery in Patients With Severe Uveitis |
| NCT03971279 | Not specified | COMPLETED | Dexamethasone Intravitreal Implant (Ozurdex®) for Recurrent Vogt-Koyanagi-Harada (VKH) Disease Posterior Uveitis |
| NCT04126850 | Not specified | UNKNOWN | Pilot Project: The Amplicon and Metatranscriptomic Study of Intra and Extra Intestinal Microbiome in Non-infectious Uveitis Disease |
Drugs tested across these trials (top 30)
| Molecule | Max phase | Trials referencing |
|---|---|---|
| CYCLOSPORINE | 4 | 1 |
| SOTRASTAURIN | 2 | 3 |
Related Atlas pages
- Drugs: Cyclosporine